Enteric-coated mycophenolate sodium

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Prevention of Acute Rejection After Kidney Transplantation

Conditions

Prevention of Acute Rejection After Kidney Transplantation

Trial Timeline

Mar 1, 2004 → Jun 1, 2005

NCT ID

NCT00171392

About Enteric-coated mycophenolate sodium

Enteric-coated mycophenolate sodium is a phase 3 stage product being developed by Novartis for Prevention of Acute Rejection After Kidney Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT00171392. Target conditions include Prevention of Acute Rejection After Kidney Transplantation.

What happened to similar drugs?

9 of 20 similar drugs in Prevention of Acute Rejection After Kidney Transplantation were approved

Approved (9) Terminated (0) Active (11)

✅RaltegravirMerckApproved

✅Meningococcal C conjugate vaccineNovartisApproved

✅Boostrix + Placebo (Saline)NovartisApproved

✅Meningococcal C conjugate vaccineNovartisApproved

✅Lenacapavir long-actingGilead SciencesApproved

✅DescovyGilead SciencesApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01467011	Pre-clinical	Completed	Dec 1, 2010	Dec 1, 2013	End Stage Liver Disease
NCT00351377	Phase 3	Completed	Jun 1, 2006	Jun 1, 2009	Autoimmune Disease
NCT00171379	Phase 3	Completed	Mar 1, 2004	Jun 1, 2005	Prevention of Acute Rejection After Kidney Transplantation
NCT00171392	Phase 3	Completed	Mar 1, 2004	Jun 1, 2005	Prevention of Acute Rejection After Kidney Transplantation
NCT00239057	Phase 3	Completed	May 1, 2002	Jan 1, 2005	Maintenance Renal Transplantation
NCT00239031	Phase 3	Completed	Mar 1, 2002	Jul 1, 2005	Denovo Renal Transplantation
NCT00574743	Approved	Completed	Jan 1, 2002	—	Heart Transplantation

Competing Products

20 competing products in Prevention of Acute Rejection After Kidney Transplantation

See all competitors

Product	Company	Stage	Hype Score
mRNA-1944	Moderna	Phase 1	0
Gam-COVID-Vac	Dr. Reddy's Laboratories	Phase 2/3	31
edoxaban + enoxaparin sodium	Daiichi Sankyo	Phase 3	40
Mifepristone	Eli Lilly	Phase 2	35
EXANTA	AstraZeneca	Phase 2	27
Risk of low dose aspirin discontinuation	AstraZeneca	Pre-clinical	26
DAPA/MET XR + DAPA + MET XR	AstraZeneca	Phase 3	40
Esomeprazole + Placebo	AstraZeneca	Phase 3	40
PCV15	Merck	Pre-clinical	18
Raltegravir	Merck	Approved	43
RotaTeq (V260) + IPV	Merck	Phase 3	40
V501	Merck	Phase 3	40
Zostavax	Merck	Phase 3	40
V920 Consistency Lot A + V920 Consistency Lot B + V920 Consistency Lot C + V920 High-dose Lot + Placebo to V920	Merck	Phase 3	40
Letermovir + Placebo	Merck	Phase 3	40
Meningococcal C conjugate vaccine	Novartis	Approved	43
Meningococcal C conjugate vaccine	Novartis	Approved	43
rMenB+OMV NZ	Novartis	Phase 3	40
Enteric-Coated Mycophenolate Sodium	Novartis	Phase 3	40
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Placebo in 1.5ml	Novartis	Phase 3	44